1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Rebus Holdings, Inc.

Rebus Holdings, Inc.

RBSH
Rebus Holdings, Inc.US flagOther OTC
0.00
USD
- -
- -
3,213.00Market Cap
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-425,783.9
-476,166.67
-532,307.69
-331,375
-368,105.26
-245,250
-132,791.67
-57,512.95
-7.98
-298.98
-10.89
0.35
-0.03
0.02
Free Cash Flow per Basic Share
-277,921.7
-312,000
-348,307.69
-294,687.5
-265,684.21
-193,208.33
-114,041.67
-5,673.58
-135.73
-100.19
-0.65
-0.09
-0.02
-0.01
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-1,444,760.8
-1,680,083.33
-2,083,153.85
-2,023,875
-2,072,421.05
-1,886,041.67
-2,026,416.67
-309,497.41
-39,750.5
-19,423.82
-115.89
-8.41
-2.05
-2.04
Tangible Book Value per Share
111,589.1
241,833.33
-66,461.54
71,375
-210.53
-83,000
-39,833.33
-46,103.63
-5,522.29
-2,792.25
-21.64
-0.66
-0.16
-0.17
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
8
32
32
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-4
-6
-7
-5
-7
-6
-3
-11
- -
-1
-6
3
-1
1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
3
5
-1
1
- -
-2
-1
-9
-8
-9
-13
-5
-5
-6
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
1
3
-1
1
- -
-2
-1
-9
-8
-9
-13
-5
-5
-6
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-5.87
- -
-0.9
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Dec'22
Mar'23
Jun'23
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
32
32
32
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Dec'22
Mar'23
Jun'23
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
5
6
6
Payables & Accruals
3
3
3
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-160.27%
-2.65%
4.28%
Free Cash Flow
-1.92%
15.74%
1.88%
Net Income, GAAP
807.19%
1,575.35%
-137.81%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-3.64
2.48
0.8
- -
0.35
2022
-0.02
-0.04
0.01
- -
-0.03
2023
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Raul Silvestre
Full Time Employees
1
Sector
Healthcare
Industry
Biotechnology
Address
2629 Townsgate Road Westlake Village CA United States of America 91361
IPO Date
Nov 4, 2009
CIK
0001421204
Website
rebus-corp.com
Similar Companies
Puma Biotechnology, Inc. (PBYI)
OS Therapies Incorporated (OSTX)
Kadmon Holdings, Inc. (KDMN)
Aceragen, Inc. (ACGN)
Tyra Biosciences, Inc. (TYRA)
Supriya Lifescience Limited (SUPRIYA.BO)
Business
Rebus Holdings, Inc. (RBSH) is a clinical-stage biotechnology company focused on the research, development, and commercialization of precision therapeutics targeting the tumor microenvironment to treat cancer; its pipeline centers on adenosine receptor modulators delivered via proprietary nano- or microparticle formulations for intratumoral administration. Core assets include RT-AR001, the lead candidate comprising an A2A adenosine receptor antagonist in nanoparticle form to enhance tumor infiltration and immune response; additional pipeline components encompass selective A2B antagonists, dual A2A/A2B antagonists, and complementary A2A agonists, all aimed at overcoming immunosuppression in solid tumors. The company operates in the immuno-oncology segment of the healthcare industry, targeting oncologists, hospitals, and strategic partners in North America with plans for global expansion; founded in 2003 and headquartered at 2629 Townsgate Road, Suite 215, Westlake Village, California, it employs a lean model with one full-time equivalent and outsources manufacturing to GMP-compliant contract organizations. In October 2021, Rebus Holdings completed a holding company reorganization from Inspyr Therapeutics, Inc., adopting the RBSH ticker and rebranding its website to rebus-corp.com while reacquiring intellectual property rights including US Patent 9,593,118 covering A2A/A2B antagonists following termination of its licensing agreement with Ridgeway Therapeutics; between September 2021 and February 2022, it manufactured GMP-grade RT-AR001 and A2A antagonists sufficient for IND-enabling studies and initial clinical trials, advancing toward an expected IND submission. The company remains pre-revenue with no recent funding rounds, acquisitions, or partnerships disclosed as of late 2025, concentrating efforts on pipeline characterization and clinical candidate selection led by CEO Raul Silvestre.